发明授权
US09382525B2 Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents
有权
精氨酸酶的定点聚乙二醇化及其作为抗癌剂和抗病毒剂的用途
- 专利标题: Site-directed pegylation of arginases and the use thereof as anti-cancer and anti-viral agents
- 专利标题(中): 精氨酸酶的定点聚乙二醇化及其作为抗癌剂和抗病毒剂的用途
-
申请号: US13945938申请日: 2013-07-19
-
公开(公告)号: US09382525B2公开(公告)日: 2016-07-05
- 发明人: Yun Chung Leung , Wai-hung Lo
- 申请人: The Hong Kong Polytechnic University
- 申请人地址: HK Hung Hom, Kowloon
- 专利权人: The Hong Kong Polytechnic University
- 当前专利权人: The Hong Kong Polytechnic University
- 当前专利权人地址: HK Hung Hom, Kowloon
- 代理机构: Ella Cheong Hong Kong
- 代理商 Sam T. Yip
- 主分类号: C12N9/78
- IPC分类号: C12N9/78 ; A61K47/48 ; A61K38/00
摘要:
The present invention provides a site-specific pegylated arginase conjugate and method for producing thereof. The site-specific pegylated arginase is homogeneous in molecular weight and shows therapeutic effect for treating cancers and viral infections. The method for producing the arginase conjugate comprises genetically modifying the gene encoding an arginase so that the PEG moiety can be attached to the enzyme at a predetermined, specific intended sites. This is achieved by removing the PEG-attaching amino acid residue(s) at undesirable site(s) while keeping or adding cysteine(s) at the desirable site(s) of the enzyme. Two exemplary embodiments of the pegylated arginase conjugate are directed to human arginase I (HAI) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys45 of the enzyme and Bacillus caldovelox arginase (BCA) where a polyethylene glycol (PEG) moiety is site-specific covalently bonded to Cys161 of the enzyme.